Cerebrospinal fluid metabolites to explore mechanisms behind neurodegenerative diseases.
Nightingale’s cerebrospinal fluid (CSF) biomarker analysis enables discovery of biomarkers related to disease onset and prognosis in neurodegenerative diseases, such as multiple sclerosis, Parkinson’s disease, ALS and dementia. The platform allows simultaneous quantification of around 30 metabolites from different metabolic pathways, including energy metabolism, fluid balance and carbohydrates.
The biomarkers come as a package and we provide all measurements listed in the CSF panel for both sample volumes—150µl and 500µl. Results are provided in molar concentration units and are therefore ready-to-use.
High-throughput technology allows analysis at competitive pricing. The cost is based on the size and volume of the sample sets. The higher the number of samples, the lower the cost of analysis per sample.
Combining our CSF and blood biomarker analysis opens up an opportunity to uncover novel molecular insights that influence neurodegenerative diseases. For instance, it can help understand how the subtle leakage of the blood-brain barrier influences the development of these diseases.
Consult our science team anytime regarding the biomarkers, the platform’s applicability, our analysis process and data results.
Gain from fully quantified biomarker results that are delivered in absolute concentration units. The data comes with detailed description of the quality of the samples to support the reliability and validity of research results.
As an additional service, our in-house data scientists can provide a full data analysis of the results, based on your chosen variants and the focus of your research.